Biomoneta, a pioneering Indian healthtech company backed by Beyond Next Ventures India (BNV India), has secured approval from the US Food and Drug Administration (US FDA) for its flagship air-decontamination system, Avata Rx. This marks the first time an Indian company has received FDA clearance in the air-decontamination category.

Powered by its proprietary ZeBox microbicidal technology, Avata Rx delivers broad-spectrum microbicidal action that inactivates airborne bacteria (including multidrug-resistant strains), viruses, fungi, hardy spores, and even Mycobacterium tuberculosis, one of the most difficult airborne pathogens to eliminate.

The platform has been independently validated across multiple testing environments, including a Department of Biotechnology–funded IISc study that showed its ability to destroy more than 10 million airborne SARS-CoV-2 particles within five minutes. With this, Avata Rx is now considered one of the most scientifically validated air-decontamination technologies globally.

Biomoneta’s products are already used across ICUs, NICUs, operating theatres, procedure rooms, ambulances and critical-care transport, as well as tissue-culture labs, biomedical research facilities, pharmaceutical cleanrooms, and change rooms, where they have demonstrated real-world reductions in microbial load—strengthening patient safety, protecting healthcare workers, and preventing contamination-related losses in biomanufacturing environments.

The FDA approval opens the door for Biomoneta to expand into regulated global markets that require clinically validated air-decontamination solutions.

Commenting on the milestone, Jay Krishnan, Partner-India, Beyond Next Ventures (BNV), said, “Biomoneta represents exactly the kind of deep-science innovation Beyond Next Ventures exists to back- Technologies built on rigorous research, validated in real-world environments, and capable of creating global impact. FDA approval is not just a regulatory milestone; it is a scientific endorsement that places Biomoneta on the world stage. We are proud to support a team turning frontier microbiology into solutions that protect lives and redefine what clean-air technology can achieve.”

Arindam Ghatak, Co-founder & CEO, Biomoneta, added, “FDA approval for Avata Rx is a powerful validation of nearly a decade of scientific persistence, engineering rigor, and an unwavering belief that clean air should be a fundamental standard of care.”

Biomoneta develops advanced air-decontamination solutions to prevent the spread of infections in healthcare and biotechnology environments. Led by a multidisciplinary team with decades of expertise in infection biology, engineering, and product development, the company focuses on reducing life-threatening microbial contamination, including multidrug-resistant organisms.